Early emphysema due to alpha 1-antitrypsin deficiency (alpha 1-ATD) in a young patient with asthma is an unusual and frequently missed diagnosis. Theoretical and clinical evidence supports the ...

Chronic obstructive pulmonary disease (COPD) remains highly prevalent among veterans, but the contribution of alpha-1 antitrypsin deficiency (AAT deficiency or AATD) to this patient population remains ...

"Our findings demonstrate that dyspnea, frequent exacerbations, and other aspects of disease severity associate with worse quality of life, particularly its physical component." -- Radmila Choate, PhD ...

Grifols’ advances in the science of alpha-1 underscore its robust innovation pipeline and commitment to testing and treatment for the alpha-1 community BARCELONA, Spain, July 13, 2023 (GLOBE NEWSWIRE) ...

Boosting levels of a deficient protein has clear survival benefits for people with the genetic condition alpha-1 antitrypsin deficiency (AATD), according to new research led by RCSI University of ...

Please provide your email address to receive an email when new articles are posted on . Direct-to-consumer testing, combined with clinical follow-up, helped identify patients with undiagnosed alpha-1 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with alpha-1 antitrypsin deficiency (AATD) ...

Some people develop chronic obstructive pulmonary disease (COPD) due to a genetic link to the condition. The most understood contributing factor to genetic COPD is an alpha-1 antitrypsin (alpha-1) ...

Researchers at Saint Louis University's School of Medicine, in collaboration with Arrowhead Pharmaceuticals and Takeda Pharmaceuticals, report the first effective drug to treat a rare, genetic liver ...

Target of 339 patients enrolled has been met in the SPARTA clinical trial, designed to evaluate efficacy and safety of two separate weekly doses of Grifols’ Prolastin ®-C (Alpha1-Proteinase Inhibitor ...

BARCELONA, Spain, July 13, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world’s leading producers of plasma-derived medicines, today announced it has met its ...